The complement system: a potential target for the comorbidity of chronic pain and depression

키워드

참고문헌 (87)

1. Raja SN, "The revised International Association for the Study of Pain definition of pain : concepts, challenges, and compromises", Pain, 161, pp.1976~1982 (2020)
2. Barroso J, "Brain mechanisms of chronic pain : critical role of translational approach", Transl Res, 238, pp.76~89 (2021)
3. Attal N, "The specific disease burden of neuropathic pain : results of a French nationwide survey", Pain, 152, pp.2836~2843 (2011)
4. Rizvi SJ, "Reward processing as a common diathesis for chronic pain and depression", Neurosci Biobehav Rev, 127, pp.749~760 (2021)
5. Zhou W, "A neural circuit for comorbid depressive symptoms in chronic pain", Nat Neurosci, 22, pp.1649~1658 (2019)
6. Pillai A, "Chronic stress and complement system in depression", Braz J Psychiatry, 44, pp.366~367 (2022)
7. Perlmutter DH, "Molecular immunobiology of complement biosynthesis : a model of singlecell control of effector-inhibitor balance", Annu Rev Immunol, 4, pp.231~251 (1986)
8. Singhrao SK, "Differential expression of individual complement regulators in the brain and choroid plexus", Lab Invest, 79, pp.1247~1259 (1999)
9. Zhang W, "C1q and central nervous system disorders", Front Immunol, 14, pp.1145649~ (2023)
10. Warwick CA, "The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain", J Biol Chem, 297, pp.101085~ (2021)
11. Tong Y, "Association of pain with plasma C5a in patients with neuromyelitis optica spectrum disorders during remission", Neuropsychiatr Dis Treat, 18, pp.1039~1046 (2022)
12. Togha M, "Proteomics analysis revealed the presence of inflammatory and oxidative stress markers in the plasma of migraine patients during the pain period", Brain Res, 1797, pp.148100~ (2022)
13. Yi D, "Identification of neuropathic pain-associated genes and pathways via random walk with restart algorithm", J Neurosurg Sci, 65, pp.414~420 (2021)
14. Wang K, "Identification of the hub genes related to nerve injury-induced neuropathic pain", Front Neurosci, 14, pp.488~ (2020)
15. Zhou J, "Zoster sine herpete : a review", Korean J Pain, 33, pp.208~215 (2020)
16. Peng Z, "Development of a model for predicting the effectiveness of pulsed radiofrequency on zoster-associated pain", Pain Ther, 11, pp.253~267 (2022)
17. Reddy PV, "Multiple complement pathway-related proteins might regulate immunopathogenesis of major depressive disorder", Clin Psychopharmacol Neurosci, 21, pp.313~319 (2023)
18. Luo X, "Plasma complement C3 and C3a are increased in major depressive disorder independent of childhood trauma", BMC Psychiatry, 22, pp.741~ (2022)
19. Yao Q, "Increased serum levels of complement C1q in major depressive disorder", J Psychosom Res, 133, pp.110105~ (2020)
20. Crider A, "Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior", Brain Behav Immun, 70, pp.246~256 (2018)
21. Westacott LJ, "Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder", Brain Behav Immun, 99, pp.70~82 (2022)
22. Tripathi A, "Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway", Mol Psychiatry, 26, pp.3043~3059 (2021)
23. Griffin RS, "Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity", J Neurosci, 27, pp.8699~8708 (2007)
24. Davoust N, "Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells", Glia, 26, pp.201~211 (1999)
25. Zhang MM, "IL-1R", C3aR signaling regulates synaptic pruning in the prefrontal cortex of depression, 2022, pp.12, 90~
26. Quadros AU, "C5a and pain development : an old molecule, a new target", Pharmacol Res, 112, pp.58~67 (2016)
27. Yasuda M, "An activity-dependent determinant of synapse elimination in the mammalian brain", Neuron, 109, pp.1333~1349 (2021)
28. Soteros BM, "Complement and microglia dependent synapse elimination in brain development", WIREs Mech Dis, 14, pp.e1545~ (2022)
29. De Leo JA, "The tetrapartite synapse : path to CNS sensitization and chronic pain", Pain, 122, pp.17~21 (2006)
30. Deng SL, "Microglia : a central player in depression", Curr Med Sci, 40, pp.391~400 (2020)
31. Lawal O, "The role of astrocyte structural plasticity in regulating neural circuit function and behavior", Glia, 70, pp.1467~1483 (2022)
32. Dejanovic B, "Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models", Nat Aging, 2, pp.837~850 (2022)
33. Filipello F, "The microglial innate immune receptor TREM2 is required for synapse elimination and normal brain connectivity", Immunity, 48, pp.979~991 (2018)
34. Schecter RW, "Experience-dependent synaptic plasticity in V1 occurs without microglial CX3CR1", J Neurosci, 37, pp.10541~10553 (2017)
35. Chung WS, "Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways", Nature, 504, pp.394~400 (2013)
36. Lee JH, "Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis", Nature, 590, pp.612~617 (2021)
37. Brown GC, "Microglial phagocytosis of live neurons", Nat Rev Neurosci, 15, pp.209~216 (2014)
38. Stevens B, "The classical complement cascade mediates CNS synapse elimination", Cell, 131, pp.1164~1178 (2007)
39. Cong Q, "The endogenous neuronal complement inhibitor SRPX2protects against complement-mediated synapse elimination during development", Nat Neurosci, 23, pp.1067~1078 (2020)
40. Lehrman EK, "CD47 protects synapses from excess microglia-mediated pruning during development", Neuron, 100, pp.120~134 (2018)
41. Lian H, "Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease", J Neurosci, 36, pp.577~589 (2016)
42. Park SY, "Engulfment signals and the phagocytic machinery for apoptotic cell clearance", Exp Mol Med, 49, pp.e331~ (2017)
43. Fonseca MI, "Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain", J Neuroinflammation, 14, pp.48~ (2017)
44. Lu JH, "The classical and regulatory functions of C1q in immunity and autoimmunity", Cell Mol Immunol, 5, pp.9~21 (2008)
45. Györffy BA, "Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning", Proc Natl Acad Sci U S A, 115, pp.6303~6308 (2018)
46. Dunkelberger JR, "Complement and its role in innate and adaptive immune responses", Cell Res, 20, pp.34~50 (2010)
47. Hong S, "Complement and microglia mediate early synapse loss in Alzheimer mouse models", Science, 352, pp.712~716 (2016)
48. Wang R, "The role of glial cell activation mediated by complement system C1q", C3in depression-like behavior in mice, 2021, pp.42, 328~337
49. Li Y, "Botulinum neurotoxin A ameliorates depressivelike behavior in a reserpine-induced Parkinson's disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation", Acta Pharmacol Sin, 44, pp.1322~1336 (2023)
50. Yuan T, "Amygdala microglia modify neuronal plasticity via complement C1q", C3-CR3 signaling and contribute to visceral pain in a rat model, 2021, pp.320, G1081~G1092
51. Coulthard LG, "Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance", Mol Immunol, 101, pp.176~181 (2018)
52. Coulthard LG, "Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth", J Immunol, 194, pp.3542~3548 (2015)
53. Li J, "hUCMSCs ameliorated CUMS-induced depression by modulating complement C3 signaling-mediated microglial polarization during astrocyte-microglia crosstalk", Brain Res Bull, 163, pp.109~119 (2020)
54. Zhang MM, "Gypenoside XVII, an active ingredient from Gynostemma pentaphyllum, inhibits C3aRassociated synaptic pruning in stressed mice", Nutrients, 14, pp.2418~ (2022)
55. Nie F, "Abnormal activation of complement C3 in the spinal dorsal horn is closely associated with progression of neuropathic pain", Int J Mol Med, 31, pp.1333~1342 (2013)
56. Mou W, "Astrocytemicroglia interaction through C3", C3aR pathway modulates neuropathic pain in rats model of chronic constriction injury, 2022, pp.18, 17448069221140532~
57. Zhu A, "C3aR in astrocytes mediates post-thoracotomy pain by inducing A1 astrocytes in male rats", Biochim Biophys Acta Mol Basis Dis, 1869, pp.166672~ (2023)
58. Andersen SL, "Neuroinflammation, early-life adversity, and brain development", Harv Rev Psychiatry, 30, pp.24~39 (2022)
59. Campos ACP, "Neuroinflammation, pain and depression : an overview of the main findings", Front Psychol, 11, pp.1825~ (2020)
60. Burke NN, "Neuroinflammatory mechanisms linking pain and depression", Mod Trends Pharmacopsychiatry, 30, pp.36~50 (2015)
61. Guo B, "Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression", Transl Psychiatry, 13, pp.5~ (2023)
62. Ricklin D, "Complement : a key system for immune surveillance and homeostasis", Nat Immunol, 11, pp.785~797 (2010)
63. Bohlson SS, "Complement in the brain : contributions to neuroprotection, neuronal plasticity, and neuroinflammation", Annu Rev Immunol, 41, pp.431~452 (2023)
64. Schartz ND, "The good, the bad, and the opportunities of the complement system in neurodegenerative disease", J Neuroinflammation, 17, pp.354~ (2020)
65. Wu X, "Complement C1q drives microglia-dependent synaptic loss and cognitive impairments in a mouse model of lipopolysaccharide-induced neuroinflammation", Neuropharmacology, 237, pp.109646~ (2023)
66. Zhou R, "Complement C3 enhances LPS-elicited neuroinflammation and neurodegeneration via the Mac1", NOX2 pathway, 2023, pp.60, 5167~5183
67. Veerhuis R, "Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q", Neurobiol Dis, 19, pp.273~282 (2005)
68. Madeshiya AK, "C1q deletion exacerbates stress-induced learned helplessness behavior and induces neuroinflammation in mice", Transl Psychiatry, 12, pp.50~ (2022)
69. Simonetti M, "Nuclear calcium signaling in spinal neurons drives a genomic program required for persistent inflammatory pain", Neuron, 77, pp.43~57 (2013)
70. Lee JD, "Complement dysregulation in the central nervous system during development and disease", Semin Immunol, 45, pp.101340~ (2019)
71. Tenner AJ, "Complement-mediated events in Alzheimer's disease : mechanisms and potential therapeutic targets", J Immunol, 204, pp.306~315 (2020)
72. Liu Y, "C5aR antagonist inhibits occurrence and progression of complement C5a induced inflammatory response of microglial cells through activating p38MAPK and ERK1", 2 signaling pathway, 2018, pp.22, 7994~8003
73. Doolen S, "Complement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling", Glia, 65, pp.1976~1989 (2017)
74. Li J, "Protection of hUC-MSCs against neuronal complement C3a receptor-mediated NLRP3 activation in CUMSinduced mice", Neurosci Lett, 741, pp.135485~ (2021)
75. Morgan M, "Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain", Mol Immunol, 94, pp.68~74 (2018)
76. Reginia A, "Assessment of complement cascade components in patients with bipolar disorder", Front Psychiatry, 9, pp.614~ (2018)
77. Ishii T, "Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia", Biochem Biophys Res Commun, 497, pp.683~688 (2018)
78. Alexander JJ, "Blood-brain barrier(BBB)and the complement landscape", Mol Immunol, 102, pp.26~31 (2018)
79. Alexander JJ, "The complement cascade : Yin-Yang in neuroinflammation--neuro-protection and-degeneration", J Neurochem, 107, pp.1169~1187 (2008)
80. Sprong T, "Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis", Blood, 102, pp.3702~3710 (2003)
81. Paczkowski NJ, "Pharmacological characterization of antagonists of the C5a receptor", Br J Pharmacol, 128, pp.1461~1466 (1999)
82. Ricklin D, "Complement-targeted therapeutics", Nat Biotechnol, 25, pp.1265~1275 (2007)
83. Tamamis P, "Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking", BMC Biophys, 7, pp.5~ (2014)
84. Moriconi A, "Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief", Proc Natl Acad Sci U S A, 111, pp.16937~16942 (2014)
85. Vicente B, "Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, noninferiority trial", Psychopharmacology(Berl), 237, pp.3357~3367 (2020)
86. Fairley LH, "Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy", J Neuroinflammation, 18, pp.76~ (2021)
87. Rupprecht R, "Neuroinflammation and psychiatric disorders : relevance of C1q, translocator protein(18 kDa)(TSPO), and neurosteroids", World J Biol Psychiatry, 23, pp.257~263 (2022)

관련 논문AI추천